{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T21:25:48Z","timestamp":1785446748173,"version":"3.56.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.cgh.2021.05.040","type":"journal-article","created":{"date-parts":[[2021,5,25]],"date-time":"2021-05-25T02:24:44Z","timestamp":1621909484000},"page":"e682-e695","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Re-evaluation of the Cardiovascular Safety Profile of Tegaserod: A Review of the Clinical Data"],"prefix":"10.1016","volume":"20","author":[{"given":"Brian E.","family":"Lacy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren M.","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William D.","family":"Chey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2021.05.040_bib1","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1053\/j.gastro.2020.04.014","article-title":"Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study","volume":"160","author":"Sperber","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2021.05.040_bib2","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1053\/j.gastro.2016.02.031","article-title":"Bowel disorders","volume":"150","author":"Lacy","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2021.05.040_bib3","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1053\/j.gastro.2019.12.021","article-title":"Prevalence of Rome IV functional bowel disorders among adults in the United States, Canada, and the United Kingdom","volume":"158","author":"Palsson","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2021.05.040_bib4","doi-asserted-by":"crossref","first-page":"2566","DOI":"10.1056\/NEJMra1607547","article-title":"Irritable bowel syndrome","volume":"376","author":"Ford","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2021.05.040_bib5","first-page":"99","article-title":"Rome criteria and a diagnostic approach to irritable bowel syndrome","volume":"6","author":"Lacy","year":"2017","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.cgh.2021.05.040_bib6","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1185\/03007995.2011.623157","article-title":"Health-related quality of life, work productivity and health care resource use associated with constipation predominant irritable bowel syndrome","volume":"27","author":"DiBonaventura","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.cgh.2021.05.040_bib7","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/jama.2015.0954","article-title":"Irritable bowel syndrome: a clinical review","volume":"313","author":"Chey","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.cgh.2021.05.040_bib8","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/S2468-1253(16)30023-1","article-title":"Pathophysiology of irritable bowel syndrome","volume":"1","author":"Holtmann","year":"2016","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.05.040_bib9","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1053\/j.gastro.2016.02.032","article-title":"Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV","volume":"150","author":"Drossman","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2021.05.040_bib10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.14309\/ajg.0000000000000485","article-title":"What causes functional gastrointestinal disorders? A proposed disease model","volume":"115","author":"Talley","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2021.05.040_bib11","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/apt.14226","article-title":"Review article: the many potential roles of intestinal serotonin (5-hydroxytryptamine, 5-HT) signalling in inflammatory bowel disease","volume":"46","author":"Coates","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2021.05.040_bib12","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/S0140-6736(01)07103-3","article-title":"Serotoninergic neuroenteric modulators","volume":"358","author":"Talley","year":"2001","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.cgh.2021.05.040_bib13","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1159\/000485409","article-title":"Pathophysiology of functional gastrointestinal disorders: a holistic overview","volume":"35","author":"Holtmann","year":"2017","journal-title":"Dig Dis"},{"key":"10.1016\/j.cgh.2021.05.040_bib14","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s10151-013-1106-8","article-title":"Serotonin receptors and their role in the pathophysiology and therapy of irritable bowel syndrome","volume":"18","author":"Stasi","year":"2014","journal-title":"Tech Coloproctol"},{"key":"10.1016\/j.cgh.2021.05.040_bib15","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1365-2036.2012.05011.x","article-title":"Systematic review: cardiovascular safety profile of 5-HT(4) agonists developed for gastrointestinal disorders","volume":"35","author":"Tack","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2021.05.040_bib16","series-title":"Zelnorm [package insert]","year":"2019"},{"key":"10.1016\/j.cgh.2021.05.040_bib17","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1046\/j.1365-2036.2001.01094.x","article-title":"Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation","volume":"15","author":"Muller-Lissner","year":"2001","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2021.05.040_bib18","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1046\/j.1365-2036.2002.01372.x","article-title":"A\u00a0randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation","volume":"16","author":"Novick","year":"2002","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2021.05.040_bib19","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/ajg.2009.223","article-title":"Efficacy of 5-HT3 antagonists and 5-HT4 agonists in irritable bowel syndrome: systematic review and meta-analysis","volume":"104","author":"Ford","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2021.05.040_bib20","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1136\/gut.2005.070789","article-title":"A\u00a0randomised controlled trial assessing the efficacy and safety of repeated tegaserod therapy in women with irritable bowel syndrome with constipation","volume":"54","author":"Tack","year":"2005","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2021.05.040_bib22","series-title":"Commission File No. 1-15024","year":"2007"},{"key":"10.1016\/j.cgh.2021.05.040_bib24","doi-asserted-by":"crossref","first-page":"e112289","DOI":"10.1371\/journal.pone.0112289","article-title":"Irritable bowel syndrome is positively related to metabolic syndrome: a population-based cross-sectional study","volume":"9","author":"Guo","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.cgh.2021.05.040_bib25","first-page":"1315","article-title":"Is there any association between irritable bowel syndrome subgroups and autonomous dysfunction","volume":"20","author":"Yildirim","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.cgh.2021.05.040_bib26","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.14309\/ajg.0000000000001313","article-title":"Tegaserod for irritable bowel syndrome with constipation in women less than 65 years of age without cardiovascular disease: pooled analyses of 4 controlled trials","volume":"116","author":"Shah","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2021.05.040_bib27","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/1440-1681.13477","article-title":"The effects of tegaserod, a gastrokinetic agent, on voltage-gated K+ channels in rabbit coronary arterial smooth muscle cells","volume":"48","author":"An","year":"2021","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"10.1016\/j.cgh.2021.05.040_bib28","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/1074248409340158","article-title":"Lack of association of tegaserod with adverse cardiovascular outcomes in a matched case-control study","volume":"14","author":"Anderson","year":"2009","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.cgh.2021.05.040_bib29","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/1074248409360357","article-title":"Tegaserod and the risk of cardiovascular ischemic events: an observational cohort study","volume":"15","author":"Loughlin","year":"2010","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.cgh.2021.05.040_bib30","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.jdiacomp.2013.07.007","article-title":"Observational research--opportunities and limitations","volume":"27","author":"Boyko","year":"2013","journal-title":"J\u00a0Diabetes Complications"},{"key":"10.1016\/j.cgh.2021.05.040_bib31","first-page":"1315","article-title":"Is there any association between irritable bowel syndrome subgroups and autonomous dysfunction","volume":"20","author":"Yildirim","year":"2016","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.cgh.2021.05.040_bib32","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1177\/1074248409340158","article-title":"Lack of association of tegaserod with adverse cardiovascular outcomes in a matched case-control study","volume":"14","author":"Anderson","year":"2009","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.cgh.2021.05.040_bib33","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/1074248409360357","article-title":"Tegaserod and the risk of cardiovascular ischemic events: an observational cohort study","volume":"15","author":"Loughlin","year":"2010","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.cgh.2021.05.040_bib34","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/j.1742-7843.2009.00507.x","article-title":"Electrophysiological characterization of isolated human atrial myocytes exposed to tegaserod","volume":"106","author":"Suffredini","year":"2010","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.cgh.2021.05.040_bib35","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/00005344-199907000-00014","article-title":"Comparison of tegaserod (HTF 919) and its main human metabolite with cisapride and erythromycin on cardiac repolarization in the isolated rabbit heart","volume":"34","author":"Drici","year":"1999","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"key":"10.1016\/j.cgh.2021.05.040_bib36","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1111\/j.1572-0241.2002.05986.x","article-title":"Tegaserod, a 5-hydroxytryptamine type 4 receptor partial agonist, is devoid of electrocardiographic effects","volume":"97","author":"Morganroth","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2021.05.040_bib37","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.vph.2012.11.002","article-title":"An in\u00a0vitro investigation of the cardiovascular effects of the 5-HT(4) receptor selective agonists, velusetrag and TD-8954","volume":"58","author":"Beattie","year":"2013","journal-title":"Vascul Pharmacol"},{"key":"10.1016\/j.cgh.2021.05.040_bib38","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/1074248420942004","article-title":"An ex\u00a0vivo study to evaluate the effect of tegaserod on platelet activation and aggregation","volume":"26","author":"Gurbel","year":"2021","journal-title":"J\u00a0Cardiovasc Pharmacol Ther"},{"key":"10.1016\/j.cgh.2021.05.040_bib39","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1124\/jpet.117.244079","article-title":"Nonclinical cardiovascular studies of prucalopride, a highly selective 5-hydroxytryptamine 4 receptor agonist","volume":"364","author":"Conlon","year":"2018","journal-title":"J\u00a0Pharmacol Exp Ther"},{"key":"10.1016\/j.cgh.2021.05.040_bib40","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00210-011-0687-x","article-title":"The inability of tegaserod to affect platelet aggregation and coronary artery tone at supratherapeutic concentrations","volume":"385","author":"Higgins","year":"2012","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.cgh.2021.05.040_bib41","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/MJT.0b013e3181b63f21","article-title":"Investigations on 5-HT(4) receptor expression and effects of tegaserod on human platelet aggregation in\u00a0vitro","volume":"17","author":"Serebruany","year":"2010","journal-title":"Am J Ther"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356521005784?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356521005784?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:38:21Z","timestamp":1761543501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356521005784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S1542356521005784"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2021.05.040","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Re-evaluation of the Cardiovascular Safety Profile of Tegaserod: A Review of the Clinical Data","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2021.05.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the AGA Institute","name":"copyright","label":"Copyright"}]}}